Prescribing information and warning labels for exenatide and liraglutide list pancreatitis as a potential side effect of their use [4]. It is anticipated that an approach to increase endogenous GLP-1 secretion rather than administering exogenous GLP-1 mimetics will be popularized. Here, GLP1R is linked to pancreatitis.